keyword
MENU ▼
Read by QxMD icon Read
search

Dupilumab

keyword
https://www.readbyqxmd.com/read/29630150/a-possible-role-for-dupilumab-dupixent-in-the-management-of-idiopathic-chronic-eczematous-eruption-of-aging
#1
Grace C Brummer, Lawrence T Wang, Richard D Sontheimer
Aging individuals can develop generalized, exquisitely-pruritic, eczematous eruptions of uncertain etiology that can be therapeutically-refractory and life-altering. Limited information exists in the literature to guide clinicians in the diagnosis and management of such patients. It is suggested that in approximately 40% of such patients a known cause for their chronic pruritic eruptions cannot be identified. In this report we will refer to this subgroup of patients as having idiopathic chronic eczematous eruption of aging (CEEA)...
February 15, 2018: Dermatology Online Journal
https://www.readbyqxmd.com/read/29606994/be-aware-dupilumab-use
#2
Linda S Marcus
No abstract text is available yet for this article.
March 2018: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/29589656/-what-s-new-in-the-management-of-atopic-dermatitis-in-children-and-adolescents
#3
Justine Czernielewski, Émilie Comte Krieger, Stéphanie Christen-Zaech
A better understanding of the atopic dermatitis (AD) pathogenesis and the need for more efficient and safer treatments in severe AD promoted the development of new therapies. Several underwent and are still undergoing clinical trials, but due to safety reasons, they include mainly adults for now. AD is however predominant in childhood with a prevalence 20 % in children compared to only 5 % in adults. Regarding the pediatric population, the new pipeline relies on two selective immunosuppressive agents, notably crisaborole (phosphodiesterase-4 inhibitor) and dupilumab (IL-4 and IL-13 inhibitor)...
March 28, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29577443/a-new-era-for-translational-atopic-dermatitis-research-and-management
#4
EDITORIAL
Kenji Kabashima, Tilo Biedermann
Detailed analyses on atopic dermatitis (AD) were performed and are ongoing in regard to the genetic basis of AD, the inflammatory signatures and immune players, risk factors and triggers, comorbidities, AD-associated pruritus, barrier dysfunction and the so called dysbiosis with severe alterations in the cutaneous microbiome (1-5). With the very recent approval of the first biologic treatment in AD (Dupilumab), we are facing a new era for affected patients and the medical and scientific community. These circumstances will be accelerating AD research as new resources will be allocated, scientists and doctors attracted to the field and this will altogether further foster development of new AD treatments...
March 25, 2018: Experimental Dermatology
https://www.readbyqxmd.com/read/29570490/patch-testing-in-a-patient-on-dupilumab
#5
Joyce W Hoot, J Desiree Douglas, Louis D Falo
No abstract text is available yet for this article.
March 22, 2018: Dermatitis
https://www.readbyqxmd.com/read/29557246/dupilumab-for-treatment-of-atopic-dermatitis
#6
Marlene Seegräber, Jerome Srour, Alexandra Walter, Macarena Knop, Andreas Wollenberg
Dupilumab is a new treatment option for patients with moderate-to-severe atopic dermatitis. It blocks IL-4/IL13-signaling and thereby inhibits receptor signaling downstream the JAK-STAT-pathway. Three of the main disease mechanisms of atopic dermatitis are affected by blocking this pathway; the decrease of skin barrier function, the class switch to IgE and the TH2-differentiation. Areas Covered: Dupilumab showed promising results in clinical trials of phase I-III. Clinical outcome parameters such as SCORAD, EASI, IGA and BSA improved with dupilumab...
March 20, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29545264/%C3%A2-dupilumab-for-atopic-dermatitis
#7
(no author information available yet)
▼Dupilumab (Dupixent - Sanofi-Aventis Groupe), a monoclonal antibody for the treatment of moderate-to-severe atopic dermatitis in adults who require systemic therapy, was licensed by the European Medicines Agency in September 2017. It is the first biological drug approved specifically for this condition. Here, we review the evidence for its efficacy and safety and consider its place in therapy.
March 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29537454/dupilumab-in-the-treatment-of-dyshidrosis-a-report-of-two-cases
#8
Gillian K Weston, Jette Hooper, Bruce E Strober
Dupilumab (Dupixent, Regeneron Pharmaceuticals and Sanofi Genzyme) is a novel biologic medication recently approved by the FDA for the treatment of moderate-to-severe atopic dermatitis in adults who have not achieved adequate control with topical medications. Dyshidrotic eczema is a distinct entity, often considered on the spectrum of atopic dermatitis, that primarily effects the palms and soles; it is often associated with considerable morbidity yet is frequently challenging to treat. We report two cases of recalcitrant dyshidrotic eczema treated successfully with dupilumab at standard dosing...
March 1, 2018: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/29535032/dupilumab-for-hand-eczema
#9
Matthew J Zirwas
No abstract text is available yet for this article.
March 10, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29503598/dupilumab-an-evidence-based-review-of-its-potential-in-the-treatment-of-atopic-dermatitis
#10
REVIEW
Panteha Eshtiaghi, Melinda J Gooderham
Introduction: Atopic dermatitis (AD) is a recurrent, pruritic inflammatory skin disease with complex immunopathogenesis characterized by a dominant TH 2 response. Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that subsequently blocks IL-4 and IL-13 signaling. It has recently been approved for the treatment of adult patients with moderate-to-severe AD whose current treatment options are limited. Aim: This article reviews the evidence of clinical efficacy, safety, and patient-reported out-come (PRO) measures from Phase I-III trials of dupilumab in adult patients with moderate-to-severe AD...
2018: Core Evidence
https://www.readbyqxmd.com/read/29498038/evaluation-of-potential-disease-mediated-drug-drug-interaction-in-patients-with-moderate-to-severe-atopic-dermatitis-receiving-dupilumab
#11
John D Davis, Ashish Bansal, David Hassman, Bolanle Akinlade, Meng Li, Zhaoyang Li, Brian Swanson, Jennifer D Hamilton, A Thomas DiCioccio
This open-label drug-drug interaction study assessed whether blockade by dupilumab of interleukin (IL)-4 and IL-13 signaling affects the pharmacokinetics of drugs metabolized by cytochrome P450 (CYP450) enzymes. The pharmacokinetics of five CYP450 substrates given orally (midazolam, omeprazole, S-warfarin, caffeine, and metoprolol, metabolized by CYP3A, CYP2C19, CYP2C9, CYP1A2 and CYP2D6, respectively) were evaluated before and 28 days after initiation of dupilumab treatment (subcutaneous 300 mg weekly) in 14 patients with moderate-to-severe atopic dermatitis...
March 2, 2018: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29494389/positive-patch-test-reaction-in-a-patient-taking-dupilumab
#12
Charles J Puza, Amber Reck Atwater
No abstract text is available yet for this article.
March 2018: Dermatitis
https://www.readbyqxmd.com/read/29472119/dupilumab-treatment-in-moderate-to-severe-atopic-dermatitis-a-systematic-review-and-meta-analysis
#13
Fa-Ping Wang, Xiao-Ju Tang, Chuan-Qi Wei, Lin-Rui Xu, Hui Mao, Feng-Ming Luo
BACKGROUND: Dupilumab, a fully human monoclonal antibody against the interleukin-4-receptor α subunit, has been developed and used in clinical trials to treat atopic dermatitis (AD). OBJECTIVE: We aimed to assess the overall efficacy and safety of dupilumab treatment in AD. METHODS: PubMed, Embase, Cochrane library databases, and the Chinese Biological Medicine (CBM) published up to September 2017 were searched. All randomized controlled trials (RCTs) of dupilumab treatment on adult patients with AD were included...
February 19, 2018: Journal of Dermatological Science
https://www.readbyqxmd.com/read/29471919/dupilumab-a-review-of-its-use-in-the-treatment-of-atopic-dermatitis
#14
Melinda J Gooderham, H Chih-Ho Hong, Panteha Eshtiaghi, Kim A Papp
Atopic dermatitis (AD) is a chronic, pruritic immune-mediated inflammatory dermatosis characterized by a T helper 2 (Th2) immune response phenotype and may be associated with systemic inflammation. Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist that inhibits IL-4 and IL-13 signaling through blockade of the shared IL-4α subunit. Blockade of IL-4/13 is effective in reducing Th2 response. Dupilumab has recently been approved in the United States and Europe for the treatment of adult patients with moderate-to-severe AD...
March 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29470609/-new-aspects-in-systemic-treatment-of-atopic-dermatitis
#15
REVIEW
T Werfel, A Wollenberg, T Pumnea, A Heratizadeh
In severe cases of atopic dermatitis (AD) systemic treatment is indicated. So far, cyclosporine and systemic glucocorticosteroids represented the only systemic treatment options approved for the indications of AD in Germany; however, from clinical practice there is increasing evidence for beneficial therapeutic effects in AD by other immunosuppressive or immunomodulatory substances, such as mycophenolate, methotrexate, alitretinoin and ustekinumab. Beyond this, ongoing research activities focus on a better understanding of genetic and immunological aspects of this chronic inflammatory skin disease...
February 22, 2018: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/29451112/-regained-freedom-for-patients-with-atopic-dermatitis-fast-and-long-term-effects-of-dupilumab
#16
T Nijsten, D J Hijnen
Dupilumab is the first and long-awaited biological for treatment of moderate to severe atopic dermatitis. In randomised clinical trials approximately 40% of patients using dupilumab 300 mg every two weeks were clear or almost clear of their eczema after 16 and 52 weeks. We now face the challenge of patient stratification to limit the budget impact of dupilumab and hope that more targeted therapies for atopic dermatitis will follow soon.
2018: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/29441557/impact-of-dupilumab-on-health-related-quality-of-life-in-patients-with-atopic-dermatitis
#17
F Rencz
No abstract text is available yet for this article.
February 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29433635/-current-and-upcoming-treatments-of-adult-atopic-dermatitis
#18
J-P Lacour
The treatment of atopic dermatitis in adults is based on the use of topical steroids and emollients. When AD is resistant to a well-conducted topical treatment, phototherapy or systemic treatments can be used: ciclosporin, methotrexate, azathioprine or mycophenolate mofetil. The therapeutic landscape of adult AD is about to change and even be revolutionized by the imminent arrival of new treatments: topical phosphodiesterase 4 inhibitors, topical or systemic JAK inhibitors, anti-IL-4 and/or antiIL-13 biotherapies (dupilumab, tralokinumab, lebrikizumab), anti-IL-31 (nemolizumab), anti-TSLP...
December 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29432961/conjunctivitis-occurring-in-atopic-dermatitis-patients-treated-with-dupilumab-clinical-characteristics-and-treatment
#19
Andreas Wollenberg, Lieneke Ariens, Stephan Thurau, Chantal van Luijk, Marlene Seegräber, Marjolein de Bruin-Weller
No abstract text is available yet for this article.
February 9, 2018: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29422431/dupilumab-for-the-treatment-of-atopic-dermatitis
#20
S Ferreira, T Torres
Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical and emotional burden. AD usually starts in early childhood and has a heterogeneous course. Emerging evidence suggests that IL-4 and IL-13 are key cytokines in the immunopathogenesis of AD. Dupilumab is a monoclonal antibody directed against IL-4 receptor α subunit, that blocks both IL-4 and IL-13 signaling. Data from Phase I-III studies revealed that dupilumab, administered as monotherapy or with topical corticosteroids, is effective and well tolerated in the treatment of adult patients with moderate-to-severe AD...
February 5, 2018: Actas Dermo-sifiliográficas
keyword
keyword
25750
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"